Moderna Starts Phase 3 Clinical Trial of Its Coronavirus Vaccine Candidate

One of the most eagerly anticipated clinical trials of our time has begun. Moderna (NASDAQ: MRNA) announced Monday that it has started inoculating patients in the phase 3 study of mRNA-1273, its coronavirus vaccine candidate.

The large-scale study will involve around 30,000 participants throughout the U.S., and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

Moderna, a young biotech, was selected to receive extra support from the U.S. government's Operation Warp Speed program, which has the goal of speeding up the development of promising vaccines and treatments for COVID-19. The COVE (coronavirus efficacy) study is placebo-controlled and randomized, and has as its primary endpoint the prevention of symptomatic cases of COVID-19. There are a number of secondary endpoints, most notably the prevention of coronavirus infection entirely.

Researchers working in a laboratory.

Image source: Getty Images.

"We look forward to this trial demonstrating the potential of our vaccine to prevent COVID-19, so that we can defeat this pandemic," said Moderna CEO Stephane Bancel.

While mRNA-1273 is one of nearly 150 coronavirus vaccine candidates being developed across the world, many observers consider it to be among the most promising. Its development has been rapid, and results from its phase 1 study indicate that it produces more than the average number of SARS-CoV-2 antibodies found in individuals who have recovered from COVID-19.

Although there had been reports of some conflict between Moderna and government officials prior to the start of the phase 3 trial, federal agencies have been showering the project with funds. Over the weekend, it was reported that BARDA nearly doubled its grant for the research to up to $955 million.

Moderna stock was trading up by around 9% as of 2:15 p.m. EDT  Monday, well outpacing the 0.5% gain of the broader equities market as measured by the S&P 500 index.

10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 2, 2020


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.